Comparative Pharmacology
Head-to-head clinical analysis: MEXITIL versus TONOCARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEXITIL versus TONOCARD.
MEXITIL vs TONOCARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mexiletine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, reducing the fast inward sodium current during phase 0 of the action potential. It shortens the action potential duration and decreases excitability in cardiac myocytes.
Class Ib antiarrhythmic agent; blocks sodium channels, decreasing the rate of phase 0 depolarization, and shortens action potential duration. Increases the fibrillation threshold of the ventricles.
200-300 mg orally every 8 hours; maximum 1200 mg/day.
Intravenous loading: 1.0-1.5 mg/kg over 10-15 minutes, followed by continuous infusion of 1-4 mg/min; maximum dose: 4 mg/min; oral: not applicable.
None Documented
None Documented
Terminal half-life: 10-17 hours (mean ~12 hours) in adults with normal renal function. Context: Requires dosing every 8 hours; half-life prolonged in hepatic impairment and congestive heart failure.
Terminal elimination half-life: 2–3 hours; prolonged to 8–12 hours in severe hepatic impairment; clinical context: requires q8h dosing for arrhythmia suppression
Renal: ~80-90% as unchanged drug and metabolites (primarily glucuronide conjugates); fecal: ~10-20% via biliary elimination. Impaired renal function prolongs elimination.
Renal: ~90% (10% unchanged, remainder as metabolites); biliary/fecal: minimal (<5%)
Category C
Category C
Antiarrhythmic (Class IB)
Antiarrhythmic (Class IB)